Apollo Therapeutics is a portfolio biopharmaceutical company that converts breakthroughs in biology and basic medical research into novel medicines. Leveraging a scalable R&D platform and partnerships with six leading universities and research institutes, it advances over 20 therapeutic programs—six in development—while also in‑licensing and acquiring clinical‑stage assets to diversify risk and accelerate growth.
Funding
$33.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Developing new medicines is costly and risky, especially when relying on limited internal discovery pipelines, leading to long timelines and high failure rates for pharmaceutical companies.
Solution
Apollo Therapeutics operates as a portfolio biopharma company that links breakthroughs from leading universities and research institutes with its own drug discovery and development expertise. By maintaining partnerships with six top academic institutions, it continuously sources novel biological insights and translates them into over 20 therapeutic programs, six of which are in active development. The company’s scalable R&D platform enables rapid progression from early discovery to preclinical and clinical stages while maintaining a diversified, low‑correlation asset base. In‑licensing and acquisition of clinical‑stage programs further accelerate portfolio growth, allowing Apollo to build a broad pipeline across multiple disease areas with capital efficiency.
Target Audience
Primary customers are pharmaceutical companies and biotech firms seeking to de‑risk their pipelines through partnership, licensing, or acquisition of novel therapeutic candidates, as well as investors focused on diversified, early‑stage drug portfolios.
Features
- Strategic access agreements with six world‑leading universities and research institutes, providing a steady flow of cutting‑edge biological targets
- Integrated discovery‑to‑development workflow that combines academic insights with industrial drug development capabilities
- Portfolio model that spreads risk across more than 20 programs, emphasizing uncorrelated therapeutic areas
- Capability to in‑license or acquire clinical‑stage assets that align with internal research synergies
- Centralized capital allocation and functional leadership to efficiently fund and manage a diversified pipeline